InvestorsHub Logo
Followers 11
Posts 573
Boards Moderated 0
Alias Born 02/12/2016

Re: None

Wednesday, 10/12/2016 7:41:50 PM

Wednesday, October 12, 2016 7:41:50 PM

Post# of 464989
Page 15
8.45 a.m OC59 - 9-Months and 12-Months Safety and Exploratory Efficacy Data of ANAVEX 2-73 in a Phase 2a Study
in Mild-to-Moderate Alzheimer’s Disease Patients
Stephen Macfarlane, MD1
, Marco Cecchi, PhD2
, Paul Maruff, PhD3
, Kristina M Kapiak4
, Christopher U Missling, PhD4
(1) Caulfield Hospital, Melbourne, Australia, (2) Neuronetrix, Louisville, KY, USA, (3) Cogstate Ltd., Melbourne, Australia, (4) Anavex Life Sciences Corp., New York, NY,

http://www.ctad-alzheimer.com/sites/ctad.prod/files/files/PROGRAMprel_CTAD2016_7oct.pdf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News